Circulogene today announced the national launch of OncoGenDx, an innovative tissue-based comprehensive genomic profiling (CGP ...
The results of the TROPION-Breast02 trial of the TROP2-targeting antibody-drug conjugate (ADC) were originally due to be ...
From bispecific engineering to clinically relevant data sourcing, evolving antibody technologies advance oncology therapeutics.
Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal Phase III IMforte ...
TipRanks on MSN
Kazia Therapeutics Partners with QIMR Berghofer for Innovative PD-L1 Degrader Program
Kazia Therapeutics ( ($KZIA) ) has shared an update. On October 7, 2025, Kazia Therapeutics announced an exclusive collaboration and in-licensing ...
Positive high-level results from the TROPION-Breast02 Phase III trial showed DATROWAY® (datopotamab deruxtecan-dlnk) demonstrated a statistically significant and clinically meaningful improvement for ...
October 2025 Datroway demonstrated statistically significant and clinically meaningful improvement in overall survival as 1st-line therapy for patients with metastatic triple-negative breast cancer ...
Work at Aligos Therapeutics Inc. has led to the discovery of new programmed cell death 1 (PDCD1; PD-1; CD279)/PD-1 ligand 1 (PD-L1; CD274) interaction inhibitors reported to be useful for the ...
What's the most attractive Big Pharma stock right now for investors? Seeking Alpha analysts weigh in. Read more here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback